Search results for "Cyclin"

showing 10 items of 1021 documents

A Definitive Pharmacophore Modelling Study on CDK2 ATP Pocket Binders: Tracing the Path of New Virtual High-Throughput Screenings

2020

Cyclin Dependent Kinases-2 (CDK2) are members of serine/threonine protein kinases family. They play an important role in the regulation events of the eukaryotic cell division cycle, especially during the G1 to S phase transition. Experimental evidence indicate that excessive expression of CDK2s should cause abnormal cell cycle regulation. Therefore, since a long time, CDK2s have been considered potential therapeutic targets for cancer therapy. In this work, onehundred and forty-nine complexes of inhibitors bound in the CDK2-ATP pocket were submitted to short MD simulations (10ns) and free energy calculation. Comparison with experimental data (K<sub>i</sub>, K<sub>d</su…

CDK20301 basic medicineComputer scienceATP pocketCancer therapyComputational biologyMolecular dynamicsTracingCommon hits approachInhibitory Concentration 5003 medical and health sciencesMolecular dynamicsAdenosine Triphosphate0302 clinical medicineNeoplasmsDrug DiscoveryHumansProtein Kinase InhibitorsThroughput (business)Eukaryotic cellMM-GBSABinding SitesbiologyCyclin-Dependent Kinase 2Cyclin-dependent kinase 2High-Throughput Screening AssaysMolecular Docking Simulation030104 developmental biology030220 oncology & carcinogenesisPharmacophore modellingPath (graph theory)biology.proteinPharmacophoreProtein BindingCurrent Drug Discovery Technologies
researchProduct

Comparing molecular dynamics-derived pharmacophore models with docking: A study on CDK-2 inhibitors

2020

Abstract We compared the performance of molecular dynamics (MD)-derived pharmacophore modeling approaches, Common Hit Approach (CHA), and the Molecular dYnamics SHAred PharmacophorE (MYSHAPE) approach, with semi-flexible constrained/unconstrained docking. The aim of this work is to enrich the hit-list of a virtual screening on CDK-2 known inhibitors as a case study. Cyclin-dependent kinases (CDKs) deregulation is associated with cancer growth. CDKs are an attractive target for anticancer agents. MD-derived pharmacophore models have been obtained with LigandScout 4.2.1. Docking analysis has been performed through Glide 7.6. The results highlighted the MYSHAPE approach has a better performanc…

CDK2Virtual screeningbiologyPharmacophore010405 organic chemistryChemistryGeneral ChemistryComputational biologyMolecular dynamics010402 general chemistry01 natural sciencesDynamic pharmacophoreLigandScout0104 chemical sciencesDockingMolecular dynamicsCyclin-dependent kinaseDocking (molecular)biology.proteinPharmacophore
researchProduct

Relationships among Bicycle Rider Behaviours, Anger, Aggression, and Crashes in Finland

2022

Riding a bicycle is increasingly encouraged as a sustainable transport solution, especially in urban areas. However, safety concerns, both perceived and actual, can significantly lower the willingness to ride among the population. To support cycling planning and policy in the double task of increasing the levels of cycling while mitigating crash risk, there is a need to better understand the behaviours and attitudes of bicycle riders. In this manuscript, we study a cohort of Finnish bicycle riders through four questionnaires, the Cycling Behaviour Questionnaire (CBQ), Cyclist Risk Perception and Regulation Scale (RPRS), Cyclist Anger Scale (CAS), and Cyclist Aggression Expression Inventory …

CYCLING ANGEREXPRESSION212 Civil and construction engineering515 PsychologySeguretat viàriaPublic Health Environmental and Occupational Healthroad safety; road user behaviour; cyclist; bicycle; behaviour questionnairebehaviour questionnaireRISKY5141 SociologycyclistGENDERComportament col·lectiubicycleroad safetySafety Risk Reliability and Qualityroad user behaviourSafety Research
researchProduct

Cadmium Recovery from Spent Ni-Cd Batteries: A Brief Review

2021

The significant increase in the demand for efficient electric energy storage during the past decade has promoted an increase in the production and use of Cd-containing batteries. On the one hand, the amount of toxic Cd-containing used batteries is growing, while on the other hand, Cd is on a list of critical raw materials (for Europe). Both of these factors call for the development of effective technology for Cd recovery from spent batteries. The present paper is aimed at providing a short review of the recent progress in Cd recovery from spent batteries. Statistical data from the past decade on the source of Cd, its global production, and Ni-Cd battery recycling are given in the introducti…

Cadmiumpyro-metallurgyMining engineering. MetallurgyWaste managementBattery recyclingcadmiumMetals and Alloysbattery recyclingTN1-997chemistry.chemical_elementRaw materialNi-Cd batteriesrecoverychemistryEnvironmental scienceElectric energy storageGeneral Materials ScienceCd-containing batteriesResearch dataMetals
researchProduct

Comparative activity of idarubicin and idarubicinol in combination with cyclosporin A in multidrug-resistant leukemia cells

1996

4-Demethoxydaunorubicin (idarubicin, IDA) is an anthracycline that has shown good cytotoxic activity in vitro against tumor cell lines displaying the multidrug-resistant (MDR) phenotype. IDA is converted in the liver into idarubicinol (2HIDA) and, in this form, seems to exert its antitumoral activity in vivo. Recent studies have shown that 2HIDA has tumoricidal activity similar to that of the parent drug when tested in vitro in sensitive neoplastic cells. In this work we compared in vitro the effects of IDA and 2HIDA used alone and in combination with 2 microM cyclosporin A (CyA) in the MDR leukemic cell lines FLCR and K562R and in their sensitive parent cell lines FLC and K562. IDA and 2HI…

Cancer ResearchAnthracyclineAntineoplastic AgentsPharmacologyBiologyToxicologyIn vivohemic and lymphatic diseasesCyclosporin aAntineoplastic Combined Chemotherapy ProtocolsTumor Cells CulturedmedicineCytotoxic T cellIdarubicinPharmacology (medical)PharmacologyAntibiotics AntineoplasticDaunorubicinnutritional and metabolic diseasesFlow CytometryDrug Resistance MultipleIn vitroMultiple drug resistanceOncologyCell cultureCyclosporineIdarubicinImmunosuppressive Agentsmedicine.drugCancer Chemotherapy and Pharmacology
researchProduct

TCDD deregulates contact inhibition in rat liver oval cells via Ah receptor, JunD and cyclin A.

2007

The aryl hydrocarbon receptor (AhR) is a transcription factor involved in physiological processes, but also mediates most, if not all, toxic responses to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). Activation of the AhR by TCDD leads to its dimerization with aryl hydrocarbon nuclear translocator (ARNT) and transcriptional activation of several phase I and II metabolizing enzymes. However, this classical signalling pathway so far failed to explain the pleiotropic hazardous effects of TCDD, such as developmental toxicity and tumour promotion. Thus, there is an urgent need to define genetic programmes orchestrated by AhR to unravel its role in physiology and toxicology. Here we show that TCDD …

Cancer ResearchAryl hydrocarbon receptor nuclear translocatorPolychlorinated Dibenzodioxinscyclin AProto-Oncogene Proteins c-junCyclin DCyclin Acell cycle controlCyclin ATetrachlorodibenzodioxinModels BiologicalDownregulation and upregulationGeneticsAnimalsRNA Small InterferingMolecular BiologyTranscription factorAryl hydrocarbon receptorCells CulturedbiologyContact InhibitionContact inhibitionCell cycleAryl hydrocarbon receptorRatsAdult Stem CellsLiverReceptors Aryl Hydrocarbonliver oval cellsbiology.proteinCancer researchJunDOncogene
researchProduct

Differences in the mechanisms of growth control in contact-inhibited and serum-deprived human fibroblasts

1997

In the present work we studied mechanisms of growth control in contact-inhibited and serum-deprived human diploid fibroblasts. The observation that the effects on [3H]thymidine incorporation and reduction of retinoblastoma gene product-phosphorylation were additive when contact-inhibition and serum-deprivation were combined led us to the conclusion that the underlying mechanisms might be different. Both contact-inhibition and serum-deprivation led to a strong decrease of cdk4-kinase-activity and cdk2-phosphorylation at Thr 160, while the total amounts of cdk4 and cdk2 remained constant. In contact-inhibited cells, we revealed a strong protein accumulation of the cdk2-inhibitor p27 and a sli…

Cancer ResearchCell Cycle ProteinsProtein Serine-Threonine KinasesRetinoblastoma ProteinCulture Media Serum-FreeS PhaseCyclin D1CyclinsProto-Oncogene ProteinsCDC2-CDC28 KinasesGeneticsmedicineHumansCyclin D1Cyclin D3PhosphorylationCyclin D3FibroblastMolecular BiologyCyclin-Dependent Kinase Inhibitor p16CyclinbiologyCell growthTumor Suppressor ProteinsCyclin-Dependent Kinase 2Cyclin-dependent kinase 2G1 PhaseCyclin-Dependent Kinase 4FibroblastsDiploidyCyclin-Dependent KinasesCulture MediaCell biologymedicine.anatomical_structureCell culturebiology.proteinbiological phenomena cell phenomena and immunitySignal transductionMicrotubule-Associated ProteinsCell DivisionCyclin-Dependent Kinase Inhibitor p27Oncogene
researchProduct

Cyclin dependent kinase-1 (Cdk-1) inhibition as a novel therapeutic strategy against pancreatic ductal adenocarcinoma (pdac)

2021

Simple Summary Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers in humans, due to late diagnosis and limited treatment possibilities. Improved treatment for PDAC patients is warranted. Cyclin-dependent kinase 1 (CDK1) is a stimulator of cell cycle progression and its activity is regularly enhanced in pancreatic cancer cells. Therefore, CDK1 has been proposed as a novel drug target to treat patients with PDAC. This review describes the potential of CDK1 inhibition as a treatment for PDAC by outlining the molecular pathways influenced by CDK1 inhibition and new therapeutic strategies. Abstract The role of CDK1 in PDAC onset and development is two-fold. Firstly, since …

Cancer ResearchCell cycle checkpointendocrine system diseasesmedicine.medical_treatmentReviewenvironment and public healthTargeted therapyCyclin-dependent kinaseCancer stem cellPancreatic cancermedicineNovel treatmentCDK1 inhibitionRC254-282Cyclin-dependent kinase 1biologyChemistryNeoplasms. Tumors. Oncology. Including cancer and carcinogensPDACPancreatic cancerCell cyclemedicine.diseaseenzymes and coenzymes (carbohydrates)Oncologybiology.proteinCancer researchStem cellbiological phenomena cell phenomena and immunityCell cycle regulation
researchProduct

Effects of resveratrol analogs on cell cycle progression, cell cycle associated proteins and 5fluoro-uracil sensitivity in human derived colon cancer…

2009

International audience; Epidemiological studies suggested that trans-resveratrol, a wine grape component, could prevent malignant tumor development. This compound also demonstrated cytostatic and cytotoxic effects on tumor cells in vitro. To obtain trans-resveratrol derivatives with a better cellular uptake and enhanced antiproliferative effects, we synthesized a triacetate derivative as well as an oligomer, epsilon-viniferin and its acetylated form, epsilon-viniferin penta-acetate. We also obtained vineatrol, a wine grape shoot extract that associates several polyphenols that may act synergistically, including trans-resveratrol and epsilon-viniferin. We show here that resveratrol triacetat…

Cancer ResearchCyclin AFluorescent Antibody TechniqueCell Cycle ProteinsMESH: Cell CycleMESH: Flow CytometryMESH : Blotting WesternResveratrolmedicine.disease_causeWine grapeMESH: Drug SynergismImmunoenzyme Techniqueschemistry.chemical_compoundMESH: PhenolsMESH : Cell Cycle ProteinsMESH : Tumor Cells CulturedMESH: StilbenesStilbenesTumor Cells CulturedMESH : Cell ProliferationMESH: Fluorescent Antibody TechniqueMESH: Antimetabolites AntineoplasticbiologyKinaseMESH : Antimetabolites AntineoplasticCell Cyclefood and beveragesDrug SynergismCell cycleFlow CytometryMESH : Colonic NeoplasmsOncologyBiochemistryColonic NeoplasmsMESH : FluorouracilFluorouracilMESH : PhenolsAntimetabolites AntineoplasticMESH : Drug SynergismMESH : Flow CytometryBlotting WesternMESH : ImmunoprecipitationMESH : StilbenesMESH: Cell Cycle ProteinsPhenolsMESH : Immunoenzyme TechniquesMESH: Cell ProliferationMESH : Cell Cycle[SDV.BBM] Life Sciences [q-bio]/Biochemistry Molecular BiologymedicineHumansImmunoprecipitationMESH: Blotting Western[SDV.BBM]Life Sciences [q-bio]/Biochemistry Molecular BiologyMESH: Tumor Cells CulturedKinase activityMESH: Immunoenzyme Techniques[ SDV.BBM ] Life Sciences [q-bio]/Biochemistry Molecular BiologyBenzofuransCell ProliferationMESH: Colonic NeoplasmsMESH: HumansMESH : BenzofuransMESH: ImmunoprecipitationMESH : HumansMESH: BenzofuransMESH : Fluorescent Antibody TechniquechemistryResveratrolCell culturebiology.proteinCarcinogenesisMESH: Fluorouracil
researchProduct

R-Roscovitine (Seliciclib) prevents DNA damage-induced cyclin A1 upregulation and hinders non-homologous end-joining (NHEJ) DNA repair.

2010

Abstract Background CDK-inhibitors can diminish transcriptional levels of cell cycle-related cyclins through the inhibition of E2F family members and CDK7 and 9. Cyclin A1, an E2F-independent cyclin, is strongly upregulated under genotoxic conditions and functionally was shown to increase NHEJ activity. Cyclin A1 outcompetes with cyclin A2 for CDK2 binding, possibly redirecting its activity towards DNA repair. To see if we could therapeutically block this switch, we analyzed the effects of the CDK-inhibitor R-Roscovitine on the expression levels of cyclin A1 under genotoxic stress and observed subsequent DNA damage and repair mechanisms. Results We found that R-Roscovitine alone was unable …

Cancer ResearchDNA RepairDNA repairDNA damageSettore MED/06 - Oncologia MedicaCyclin DCyclin ACyclin BSettore BIO/11 - Biologia Molecolarelcsh:RC254-282RoscovitineProtein Kinase InhibitorsBIO/10 Biochimicaroscovitine doxorubicinbiologyResearchCyclin A1; Doxorubicin; Protein Kinase Inhibitors; Purines; Up-Regulation; DNA Damage; DNA Repair; Hydrogen-Ion Concentration; Cancer Research; Molecular Medicine; OncologyG2-M DNA damage checkpointHydrogen-Ion Concentrationlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensUp-RegulationOncologyDoxorubicinPurinesCancer researchbiology.proteinMolecular MedicineCyclin A1biological phenomena cell phenomena and immunityCyclin A1Cyclin A2DNA DamageMolecular cancer
researchProduct